Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.

Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD; INSIGHT FLU-IVIG Study Group.

Lancet Respir Med. 2019 Sep 30. pii: S2213-2600(19)30253-X. doi: 10.1016/S2213-2600(19)30253-X. [Epub ahead of print]

2.

The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE).

Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler V, Holland TL; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2019 Jun 3. pii: ciz460. doi: 10.1093/cid/ciz460. [Epub ahead of print]

PMID:
31157370
3.

Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.

Holland TL, Raad I, Boucher HW, Anderson DJ, Cosgrove SE, Aycock PS, Baddley JW, Chaftari AM, Chow SC, Chu VH, Carugati M, Cook P, Corey GR, Crowley AL, Daly J, Gu J, Hachem R, Horton J, Jenkins TC, Levine D, Miro JM, Pericas JM, Riska P, Rubin Z, Rupp ME, Schrank J Jr, Sims M, Wray D, Zervos M, Fowler VG Jr; Staphylococcal Bacteremia Investigators.

JAMA. 2018 Sep 25;320(12):1249-1258. doi: 10.1001/jama.2018.13155.

4.

Two for the price of one: emerging carbapenemases in a returning traveller to New York City.

Mittal J, Szymczak WA, Guo Y, Levi MH, Chen L, Kreiswirth BN, Riska PF, Nori P.

BMJ Case Rep. 2018 Jul 18;2018. pii: bcr-2018-225440. doi: 10.1136/bcr-2018-225440.

PMID:
30021742
5.

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection.

Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T.

BMC Infect Dis. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9.

6.

Toxocariasis presenting as eosinophilic ascites in a post-partum female.

Guha M, Jariwala S, Jinjolova N, Mazer N, Revere E, Riska P, Jerschow E.

J Parasit Dis. 2015 Jun;39(2):284-6. doi: 10.1007/s12639-013-0331-4. Epub 2013 Jul 9.

7.

Lessons learned from implementing Clostridium difficile-focused antibiotic stewardship interventions.

Ostrowsky B, Ruiz R, Brown S, Chung P, Koppelman E, van Deusen Lukas C, Guo Y, Jalon H, Sumer Z, Araujo C, Sirtalan I, Brown C, Riska P, Currie B.

Infect Control Hosp Epidemiol. 2014 Oct;35 Suppl 3:S86-95. doi: 10.1086/677828.

PMID:
25222903
8.

Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection.

Boyanton BL Jr, Sural P, Loomis CR, Pesta C, Gonzalez-Krellwitz L, Robinson-Dunn B, Riska P.

J Clin Microbiol. 2012 Mar;50(3):640-5. doi: 10.1128/JCM.01014-11. Epub 2011 Dec 21.

9.
10.

In vitro models of acute and long-term continuous infection of human respiratory epithelial cells with Chlamydophila pneumoniae have opposing effects on host cell apoptosis.

Kohlhoff SA, Kutlin A, Riska P, Roblin PM, Roman C, Hammerschlag MR.

Microb Pathog. 2008 Jan;44(1):34-42. Epub 2007 Aug 14.

PMID:
17888618
11.

Tigecycline: a glycylcycline antimicrobial agent.

Doan TL, Fung HB, Mehta D, Riska PF.

Clin Ther. 2006 Aug;28(8):1079-1106. doi: 10.1016/j.clinthera.2006.08.011. Review.

PMID:
16982286
12.

Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.

Kutlin A, Kohlhoff S, Roblin P, Hammerschlag MR, Riska P.

Antimicrob Agents Chemother. 2005 Mar;49(3):903-7.

13.

Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Riska PF, Kutlin A, Ajiboye P, Cua A, Roblin PM, Hammerschlag MR.

Antimicrob Agents Chemother. 2004 Sep;48(9):3586-90.

14.

Photographic and luminometric detection of luciferase reporter phages for drug susceptibility testing of clinical Mycobacterium tuberculosis isolates.

Hazbón MH, Guarín N, Ferro BE, Rodríguez AL, Labrada LA, Tovar R, Riska PF, Jacobs WR Jr.

J Clin Microbiol. 2003 Oct;41(10):4865-9.

15.

Rapid identification and susceptibility testing of Mycobacterium tuberculosis from MGIT cultures with luciferase reporter mycobacteriophages.

Banaiee N, Bobadilla-del-Valle M, Riska PF, Bardarov S Jr, Small PM, Ponce-de-Leon A, Jacobs WR Jr, Hatfull GF, Sifuentes-Osornio J.

J Med Microbiol. 2003 Jul;52(Pt 7):557-61.

PMID:
12808076
16.

Detection and drug-susceptibility testing of M. tuberculosis from sputum samples using luciferase reporter phage: comparison with the Mycobacteria Growth Indicator Tube (MGIT) system.

Bardarov S Jr, Dou H, Eisenach K, Banaiee N, Ya Su, Chan J, Jacobs WR Jr, Riska PF.

Diagn Microbiol Infect Dis. 2003 Jan;45(1):53-61.

PMID:
12573551
17.

Latent tuberculosis: models, mechanisms, and novel prospects for eradication.

Riska PF, Carleton S.

Semin Pediatr Infect Dis. 2002 Oct;13(4):263-72. Review.

PMID:
12491232
18.

Effectiveness of directly observed therapy (DOT) for tuberculosis: a review of multinational experience reported in 1990-2000.

Hill AR, Manikal VM, Riska PF.

Medicine (Baltimore). 2002 May;81(3):179-93. Review. No abstract available.

19.

Luciferase reporter mycobacteriophages for detection, identification, and antibiotic susceptibility testing of Mycobacterium tuberculosis in Mexico.

Banaiee N, Bobadilla-Del-Valle M, Bardarov S Jr, Riska PF, Small PM, Ponce-De-Leon A, Jacobs WR Jr, Hatfull GF, Sifuentes-Osornio J.

J Clin Microbiol. 2001 Nov;39(11):3883-8.

20.

Molecular determinants of drug resistance in tuberculosis.

Riska PF, Jacobs WR Jr, Alland D.

Int J Tuberc Lung Dis. 2000 Feb;4(2 Suppl 1):S4-10. Review.

PMID:
10688142
21.

Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.

Riska PS, Joseph DP, Dinallo RM, Davidson WC, Keirns JJ, Hattox SE.

Drug Metab Dispos. 1999 Dec;27(12):1434-47.

PMID:
10570025
22.

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J.

Drug Metab Dispos. 1999 Aug;27(8):895-901.

PMID:
10421616
23.

Rapid film-based determination of antibiotic susceptibilities of Mycobacterium tuberculosis strains by using a luciferase reporter phage and the Bronx Box.

Riska PF, Su Y, Bardarov S, Freundlich L, Sarkis G, Hatfull G, Carrière C, Kumar V, Chan J, Jacobs WR Jr.

J Clin Microbiol. 1999 Apr;37(4):1144-9.

24.

The use of luciferase-reporter phage for antibiotic-susceptibility testing of mycobacteria.

Riska PF, Jacobs WR Jr.

Methods Mol Biol. 1998;101:431-55. No abstract available.

PMID:
9921495
25.

Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy.

Krämer S, Görich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N, Brambs HJ, Sokiranski R.

Br J Radiol. 1997 Oct;70(838):995-9.

PMID:
9404201
26.

Conditionally replicating luciferase reporter phages: improved sensitivity for rapid detection and assessment of drug susceptibility of Mycobacterium tuberculosis.

Carrière C, Riska PF, Zimhony O, Kriakov J, Bardarov S, Burns J, Chan J, Jacobs WR Jr.

J Clin Microbiol. 1997 Dec;35(12):3232-9.

27.
28.
29.

A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor.

Farina PR, Graham AG, Homon CA, Lazer ES, Hattox SE, Riska PS, Gundel RH, Wegner CD.

J Pharmacol Exp Ther. 1993 May;265(2):483-9.

PMID:
8388452
30.
32.

Immune recognition of influenza virus haemagglutinin.

Skehel JJ, Barnet BC, Burt DS, Daniels RS, Douglas AR, Graham CM, Hodgson J, Knossow M, Mills KH, Riska PF, et al.

Philos Trans R Soc Lond B Biol Sci. 1989 Jun 12;323(1217):479-83; discussion 483-5.

PMID:
2569205
33.

The disposition and metabolism of 14C-tiaramide . HCl in man.

Klunk LJ, Riska PS, Maynard DE.

Drug Metab Dispos. 1982 May-Jun;10(3):241-5.

PMID:
6125356

Supplemental Content

Support Center